Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesNexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Onyx Pharmaceuticals, 07/23/09
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. announced that their first cooperative group–sponsored randomized Phase 2 trial in advanced metastatic breast cancer met its primary endpoint of progression–free survival. The study evaluated Nexavar tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER–2 negative breast cancer. Study findings demonstrated that the median progression–free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant. In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors
Chemotherapy, 12/11/09
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
The Lancet - Early Online Publication, 12/11/09
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism
Alimentary Pharmacology and Therapeutics, 12/10/09
Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD)
Archives of Gerontology and Geriatrics, 12/09/09
Subcutaneous Sumatriptan Pharmacokinetics: Delimiting the Monoamine Oxidase Inhibitor Effect
Headache: The Journal of Head and Face Pain, 12/08/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/11/09
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor